WANBURY
|
WANBURY Last 5 Year Financial Ratios History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 9.32 | 17.09 | -3.18 | 24.94 | -5.04 |
| CEPS(Rs) | 13.38 | 21.07 | 0.61 | 28.45 | -1.14 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | 15.69 | 6.44 | -10.57 | -7.55 | -62.60 |
| Tax Rate(%) | -3.31 | 0.68 | -1.06 | -0.43 | -1.61 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 11.22 | 12.37 | 4.53 | 6.17 | 3.97 |
| EBIT Margin(%) | 11.02 | 14.67 | 2.18 | 19.77 | 2.71 |
| Pre Tax Margin(%) | 4.90 | 9.66 | -2.02 | 15.77 | -3.15 |
| PAT Margin (%) | 5.06 | 9.60 | -2.04 | 15.83 | -3.20 |
| Cash Profit Margin (%) | 7.27 | 11.83 | 0.39 | 18.06 | -0.72 |
| Performance Ratios | |||||
| ROA(%) | 8.20 | 17.61 | -3.22 | 25.85 | -4.51 |
| ROE(%) | 84.21 | - | - | - | - |
| ROCE(%) | 35.97 | 101.56 | 29.82 | 428.78 | 87.61 |
| Asset Turnover(x) | 1.62 | 1.83 | 1.58 | 1.63 | 1.41 |
| Sales/Fixed Asset(x) | 2.23 | 2.39 | 2.18 | 2.32 | 1.88 |
| Working Capital/Sales(x) | 32.04 | -11.19 | -2.57 | -2.73 | -1.53 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.45 | 0.42 | 0.46 | 0.43 | 0.53 |
| Receivable days | 61.39 | 49.39 | 47.23 | 34.50 | 39.45 |
| Inventory Days | 22.30 | 18.16 | 25.70 | 26.45 | 17.17 |
| Payable days | 186.68 | 187.23 | 197.43 | 190.42 | 210.79 |
| Valuation Parameters | |||||
| PER(x) | 25.19 | 8.54 | - | 3.41 | - |
| PCE(x) | 17.54 | 6.92 | 61.38 | 2.99 | -72.77 |
| Price/Book(x) | 14.96 | 22.63 | -3.53 | -11.25 | -1.33 |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 1.55 | 1.01 | 0.36 | 0.62 | 0.91 |
| EV/Core EBITDA(x) | 11.64 | 7.96 | 7.57 | 8.67 | 17.44 |
| EV/EBIT(x) | 13.98 | 6.79 | 16.41 | 3.14 | 33.39 |
| EV/CE(x) | 4.00 | 4.23 | 5.84 | 0.92 | 1.26 |
| M Cap / Sales | 1.28 | 0.83 | 0.24 | 0.54 | 0.53 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 3.77 | 15.63 | -2.26 | 30.23 | 6.82 |
| Core EBITDA Growth(%) | 9.34 | 203.06 | -34.59 | 80.29 | -16.93 |
| EBIT Growth(%) | -22.24 | 669.96 | -89.08 | 853.58 | -89.06 |
| PAT Growth(%) | -45.44 | 638.26 | -112.76 | 746.33 | -119.56 |
| EPS Growth(%) | -45.48 | 637.60 | -112.74 | 594.95 | -119.54 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 3.37 | 5.18 | -1.86 | -2.72 | -1.02 |
| Current Ratio(x) | 1.11 | 0.75 | 0.38 | 0.48 | 0.27 |
| Quick Ratio(x) | 0.89 | 0.58 | 0.31 | 0.34 | 0.20 |
| Interest Cover(x) | 1.80 | 2.93 | 0.52 | 4.94 | 0.46 |
| Total Debt/Mcap(x) | 0.23 | 0.23 | 0.53 | 0.24 | 0.77 |
Compare Financial Ratios of peers of WANBURY
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| WANBURY | ₹818.2 Cr | -7.6% | -8% | -2.1% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹398,218.0 Cr | -0.7% | 3% | -13.4% | Stock Analytics | |
| DIVIS LABORATORIES | ₹175,158.0 Cr | 1.9% | 8.3% | 5.8% | Stock Analytics | |
| CIPLA | ₹126,710.0 Cr | 0.5% | 0.7% | -2.6% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹119,586.0 Cr | -0.1% | NA | 1.2% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹103,496.0 Cr | -2% | -5.4% | -7.5% | Stock Analytics | |
WANBURY Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| WANBURY | -7.6% |
-8% |
-2.1% |
| SENSEX | 1.6% |
2.1% |
2.6% |
You may also like the below Video Courses
